Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6,036 INR | -1.07% | +4.36% | +4.10% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's enterprise value to sales, at 3.36 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.10% | 12.16B | B+ | ||
+47.49% | 779B | C+ | ||
+40.67% | 631B | B | ||
-6.77% | 354B | C+ | ||
+20.41% | 333B | B- | ||
+8.60% | 301B | C+ | ||
+16.75% | 249B | B+ | ||
-1.19% | 216B | A+ | ||
+10.85% | 214B | B- | ||
+4.52% | 163B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DRREDDY Stock
- Ratings Dr. Reddy's Laboratories Limited